Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/48291 |
Resumo: | 1 Laboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 2 Programa Acadeˆ mico de Tuberculose da Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 3 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States, 4 Laboratório de Micobacteriologia Molecular, Faculdade de Medicina e Complexo Hospitalar Hospital Universita´ rio Clementino Fraga Filho—Instituto de Doenças do Tórax da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 5 Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil, 6 Instituto Brasileiro para Investigação da Tuberculose, Fundação Jose´ Silveira, Salvador, Brazil, 7 Gerência de Micobacteriologia, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil, 8 Laborato´ rio de Inflamac¸ão e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil, 9 Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil, 10 Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States, 11 Secretaria Municipal de Sau´ de do Rio de Janeiro, Rio de Janeiro, Brazil, 12 Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 13 Curso de Medicina, Escola Bahiana de Medicina e Saú de Pública, Salvador, Brazil, 14 Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil, 15 Laborato´ rio Reconhecer Biologia, Centro de Biociência e Biotecniologia, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Rio de Janeiro, Brazil |
id |
CRUZ_3704b3a18e037ac9e4d7787fff13dc12 |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/48291 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Carvalho, Anna Cristina C.Amorim, GustavoMelo, Mayla G. M.Silveira, Ana Karla A.Vargas, Pedro H. L.Moreira, Adriana S. R.Rocha, Michael SantosSouza, Alexandra B.Arriaga Gutiérrez, María BelenPereira, Mariana AraújoFigueiredo, Marina C.Durovni, BetinaSilva, José R. Lapa eCavalcante, SolangeRolla, Valeria C.Sterling, Timothy R.Santos, Marcelo CordeiroAndrade, Bruno de BezerrilSilva, Elisangela C.Kritski, Afrânio L.RePORT Brazil consortium2021-07-20T11:21:30Z2021-07-20T11:21:30Z2021CARVALHO, Anna Cristina C. et al. Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study. Frontiers in Immunology, 2021.1664-3224https://www.arca.fiocruz.br/handle/icict/4829110.3389/fimmu.2021.6619341 Laboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 2 Programa Acadeˆ mico de Tuberculose da Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 3 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States, 4 Laboratório de Micobacteriologia Molecular, Faculdade de Medicina e Complexo Hospitalar Hospital Universita´ rio Clementino Fraga Filho—Instituto de Doenças do Tórax da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 5 Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil, 6 Instituto Brasileiro para Investigação da Tuberculose, Fundação Jose´ Silveira, Salvador, Brazil, 7 Gerência de Micobacteriologia, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil, 8 Laborato´ rio de Inflamac¸ão e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil, 9 Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil, 10 Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States, 11 Secretaria Municipal de Sau´ de do Rio de Janeiro, Rio de Janeiro, Brazil, 12 Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 13 Curso de Medicina, Escola Bahiana de Medicina e Saú de Pública, Salvador, Brazil, 14 Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil, 15 Laborato´ rio Reconhecer Biologia, Centro de Biociência e Biotecniologia, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Rio de Janeiro, BrazilDepartamento de Ciência e Tecnologia, Ministério da Saúde, Brazil and the National Institutes of Allergy and Infectious Diseases, USA. The work of AK, BA, ES, GA, AC, MF, JL, SC, VR, BD, TS, and MC-S was supported by grants from NIH (U01AI069923, R01AI120790). BA, AK, and JL are senior scientists from the Conselho Nacional de Desenvolvimento Cientı́fico e Tecnológico (CNPq). MM received a scholarship from CNPq. MA received a scholarship from Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). MA-P received a research fellowship from the Coordenação de Aperfeiçoamento de Pessoal de Nı́vel Superior (CAPES, finance code: 001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."Múltipla ver em Notas"Neutrophils have been associated with lung tissue damage in many diseases, including tuberculosis (TB). Whether neutrophil count can serve as a predictor of adverse treatment outcomes is unknown. Methods: We prospectively assessed 936 patients (172 HIV-seropositive) with cultureconfirmed pulmonary TB, enrolled in a multicenter prospective cohort study from different regions in Brazil, from June 2015 to June 2019, and were followed up to two years. TB patients had a baseline visit before treatment (month 0) and visits at month 2 and 6 (or at the end of TB treatment). Smear microscopy, and culture for Mycobacterium tuberculosis (MTB) were performed at TB diagnosis and during follow-up. Complete blood counts were measured at baseline. Treatment outcome was defined as either unfavorable (death, treatment failure or TB recurrence) or favorable (cure or treatment completion). We performed multivariable logistic regression, with propensity score regression adjustment, to estimate the association between neutrophil count with MTB culture result at month 2 and unfavorable treatment outcome. We used a propensity score adjustment instead of a fully adjusted regression model due to the relatively low number of outcomes. Results: Among 682 patients who had MTB culture results at month 2, 40 (5.9%) had a positive result. After regression with propensity score adjustment, no significant association between baseline neutrophil count (103/mm3) and positive MTB culture at month 2 was found among either HIV-seronegative (OR = 1.06, 95% CI = [0.95;1.19] or HIV-seropositive patients (OR = 0.77, 95% CI = [0.51; 1.20]). Of 691 TB patients followed up for at least 18 months and up to 24 months, 635 (91.9%) were either cured or completed treatment, and 56 (8.1%) had an unfavorable treatment outcome. A multivariable regression with propensity score adjustment found an association between higher neutrophil count (103/mm3) at baseline and unfavorable outcome among HIV-seronegative patients [OR= 1.17 (95% CI= [1.06;1.30]). In addition, adjusted Cox regression found that higher baseline neutrophil count (103/mm3) was associated with unfavorable treatment outcomes overall and among HIV-seronegative patients (HR= 1.16 (95% CI = [1.05;1.27]). Conclusion: Increased neutrophil count prior to anti-TB treatment initiation was associated with unfavorable treatment outcomes, particularly among HIV-seronegative patients. Further prospective studies evaluating neutrophil count in response to drug treatment and association with TB treatment outcomes are warranted.engFrontiers MediaTuberculoseNeutrófilosTratamentoBiomarcadoresContagem de neutrófilosTuberculosisNeutrophilsTreatment outcomeBiomarkersNeutrophil countPre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83097https://www.arca.fiocruz.br/bitstream/icict/48291/1/license.txt36b51ef91c52b5338d9d29ba0cc807bcMD51ORIGINALCarvalho, Anna Cristina C Pre-treatment....pdfCarvalho, Anna Cristina C Pre-treatment....pdfapplication/pdf982087https://www.arca.fiocruz.br/bitstream/icict/48291/2/Carvalho%2c%20Anna%20Cristina%20C%20Pre-treatment....pdf800d01dcb2d963da9bcb23059b8678efMD52TEXTCarvalho, Anna Cristina C Pre-treatment....pdf.txtCarvalho, Anna Cristina C Pre-treatment....pdf.txtExtracted texttext/plain56074https://www.arca.fiocruz.br/bitstream/icict/48291/3/Carvalho%2c%20Anna%20Cristina%20C%20Pre-treatment....pdf.txt133133ca6bc7710c0bee99f11ef27bafMD53icict/482912023-03-15 14:34:13.922oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:34:13Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.pt_BR.fl_str_mv |
Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study |
title |
Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study |
spellingShingle |
Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study Carvalho, Anna Cristina C. Tuberculose Neutrófilos Tratamento Biomarcadores Contagem de neutrófilos Tuberculosis Neutrophils Treatment outcome Biomarkers Neutrophil count |
title_short |
Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study |
title_full |
Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study |
title_fullStr |
Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study |
title_full_unstemmed |
Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study |
title_sort |
Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study |
author |
Carvalho, Anna Cristina C. |
author_facet |
Carvalho, Anna Cristina C. Amorim, Gustavo Melo, Mayla G. M. Silveira, Ana Karla A. Vargas, Pedro H. L. Moreira, Adriana S. R. Rocha, Michael Santos Souza, Alexandra B. Arriaga Gutiérrez, María Belen Pereira, Mariana Araújo Figueiredo, Marina C. Durovni, Betina Silva, José R. Lapa e Cavalcante, Solange Rolla, Valeria C. Sterling, Timothy R. Santos, Marcelo Cordeiro Andrade, Bruno de Bezerril Silva, Elisangela C. Kritski, Afrânio L. RePORT Brazil consortium |
author_role |
author |
author2 |
Amorim, Gustavo Melo, Mayla G. M. Silveira, Ana Karla A. Vargas, Pedro H. L. Moreira, Adriana S. R. Rocha, Michael Santos Souza, Alexandra B. Arriaga Gutiérrez, María Belen Pereira, Mariana Araújo Figueiredo, Marina C. Durovni, Betina Silva, José R. Lapa e Cavalcante, Solange Rolla, Valeria C. Sterling, Timothy R. Santos, Marcelo Cordeiro Andrade, Bruno de Bezerril Silva, Elisangela C. Kritski, Afrânio L. RePORT Brazil consortium |
author2_role |
author author author author author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Carvalho, Anna Cristina C. Amorim, Gustavo Melo, Mayla G. M. Silveira, Ana Karla A. Vargas, Pedro H. L. Moreira, Adriana S. R. Rocha, Michael Santos Souza, Alexandra B. Arriaga Gutiérrez, María Belen Pereira, Mariana Araújo Figueiredo, Marina C. Durovni, Betina Silva, José R. Lapa e Cavalcante, Solange Rolla, Valeria C. Sterling, Timothy R. Santos, Marcelo Cordeiro Andrade, Bruno de Bezerril Silva, Elisangela C. Kritski, Afrânio L. RePORT Brazil consortium |
dc.subject.other.pt_BR.fl_str_mv |
Tuberculose Neutrófilos Tratamento Biomarcadores Contagem de neutrófilos |
topic |
Tuberculose Neutrófilos Tratamento Biomarcadores Contagem de neutrófilos Tuberculosis Neutrophils Treatment outcome Biomarkers Neutrophil count |
dc.subject.en.pt_BR.fl_str_mv |
Tuberculosis Neutrophils Treatment outcome Biomarkers Neutrophil count |
description |
1 Laboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 2 Programa Acadeˆ mico de Tuberculose da Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 3 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States, 4 Laboratório de Micobacteriologia Molecular, Faculdade de Medicina e Complexo Hospitalar Hospital Universita´ rio Clementino Fraga Filho—Instituto de Doenças do Tórax da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 5 Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil, 6 Instituto Brasileiro para Investigação da Tuberculose, Fundação Jose´ Silveira, Salvador, Brazil, 7 Gerência de Micobacteriologia, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil, 8 Laborato´ rio de Inflamac¸ão e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil, 9 Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil, 10 Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States, 11 Secretaria Municipal de Sau´ de do Rio de Janeiro, Rio de Janeiro, Brazil, 12 Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 13 Curso de Medicina, Escola Bahiana de Medicina e Saú de Pública, Salvador, Brazil, 14 Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil, 15 Laborato´ rio Reconhecer Biologia, Centro de Biociência e Biotecniologia, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Rio de Janeiro, Brazil |
publishDate |
2021 |
dc.date.accessioned.fl_str_mv |
2021-07-20T11:21:30Z |
dc.date.available.fl_str_mv |
2021-07-20T11:21:30Z |
dc.date.issued.fl_str_mv |
2021 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
CARVALHO, Anna Cristina C. et al. Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study. Frontiers in Immunology, 2021. |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/48291 |
dc.identifier.issn.pt_BR.fl_str_mv |
1664-3224 |
dc.identifier.doi.none.fl_str_mv |
10.3389/fimmu.2021.661934 |
identifier_str_mv |
CARVALHO, Anna Cristina C. et al. Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study. Frontiers in Immunology, 2021. 1664-3224 10.3389/fimmu.2021.661934 |
url |
https://www.arca.fiocruz.br/handle/icict/48291 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Frontiers Media |
publisher.none.fl_str_mv |
Frontiers Media |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/48291/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/48291/2/Carvalho%2c%20Anna%20Cristina%20C%20Pre-treatment....pdf https://www.arca.fiocruz.br/bitstream/icict/48291/3/Carvalho%2c%20Anna%20Cristina%20C%20Pre-treatment....pdf.txt |
bitstream.checksum.fl_str_mv |
36b51ef91c52b5338d9d29ba0cc807bc 800d01dcb2d963da9bcb23059b8678ef 133133ca6bc7710c0bee99f11ef27baf |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1813009223153352704 |